Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MED NASDAQ:NATR NASDAQ:NUTR NASDAQ:VERU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMEDMEDIFAST$14.21+1.7%$13.91$11.57▼$21.98$153.54M0.82151,110 shs115,041 shsNATRNature's Sunshine Products$17.01+0.3%$15.99$11.01▼$18.06$299.10M1.11104,176 shs73,727 shsNUTRNusatrip$5.34+10.3%$0.00$24.92▼$42.45$100.48MN/A1.08 million shs1.50 million shsVERUVeru$3.54+2.6%$4.34$2.64▼$14.20$50.57M-0.73128,146 shs105,080 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMEDMEDIFAST0.00%+3.20%+5.98%+3.12%-26.04%NATRNature's Sunshine Products0.00%-1.05%+2.54%+14.52%+20.63%NUTRNusatrip0.00%+9.65%-87.22%-87.22%-87.22%VERUVeru0.00%+2.37%-3.90%-42.48%-58.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMEDMEDIFAST$14.21+1.7%$13.91$11.57▼$21.98$153.54M0.82151,110 shs115,041 shsNATRNature's Sunshine Products$17.01+0.3%$15.99$11.01▼$18.06$299.10M1.11104,176 shs73,727 shsNUTRNusatrip$5.34+10.3%$0.00$24.92▼$42.45$100.48MN/A1.08 million shs1.50 million shsVERUVeru$3.54+2.6%$4.34$2.64▼$14.20$50.57M-0.73128,146 shs105,080 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMEDMEDIFAST0.00%+3.20%+5.98%+3.12%-26.04%NATRNature's Sunshine Products0.00%-1.05%+2.54%+14.52%+20.63%NUTRNusatrip0.00%+9.65%-87.22%-87.22%-87.22%VERUVeru0.00%+2.37%-3.90%-42.48%-58.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMEDMEDIFAST 2.00Hold$16.5016.12% UpsideNATRNature's Sunshine Products 3.00Buy$20.5020.52% UpsideNUTRNusatrip 0.00N/AN/AN/AVERUVeru 3.00Buy$33.33841.62% UpsideCurrent Analyst Ratings BreakdownLatest NUTR, NATR, MED, and VERU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025VERUVeruRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $20.008/1/2025NATRNature's Sunshine ProductsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $22.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMEDMEDIFAST$602.46M0.26$2.99 per share4.76$19.21 per share0.74NATRNature's Sunshine Products$454.36M0.66$1.25 per share13.58$8.71 per share1.95NUTRNusatripN/AN/AN/AN/AN/AN/AVERUVeru$16.89M3.07N/AN/A$2.21 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMEDMEDIFAST$2.09M$0.3244.419.29N/A0.76%2.00%1.50%11/3/2025 (Estimated)NATRNature's Sunshine Products$7.70M$0.7422.99∞N/A3.06%10.19%6.71%11/6/2025 (Estimated)NUTRNusatripN/AN/A0.00∞N/AN/AN/AN/AN/AVERUVeru-$37.80M-$2.20N/AN/AN/AN/A-143.24%-85.22%N/ALatest NUTR, NATR, MED, and VERU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q2 2025NUTRNusatripN/A$0.25N/A$0.25N/A$0.99 million8/12/2025Q3 2025VERUVeru-$0.55-$0.50+$0.05-$0.50N/AN/A8/4/2025Q2 2025MEDMEDIFAST-$0.22$0.04+$0.26$0.22$96.10 million$105.56 million7/31/2025Q2 2025NATRNature's Sunshine Products$0.1650$0.35+$0.1850$0.28$113.10 million$114.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMEDMEDIFASTN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/ANUTRNusatripN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMEDMEDIFASTN/A4.473.82NATRNature's Sunshine ProductsN/A2.271.35NUTRNusatripN/AN/AN/AVERUVeruN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMEDMEDIFAST95.51%NATRNature's Sunshine Products79.40%NUTRNusatripN/AVERUVeru47.16%Insider OwnershipCompanyInsider OwnershipMEDMEDIFAST2.90%NATRNature's Sunshine Products5.60%NUTRNusatripN/AVERUVeru15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMEDMEDIFAST87010.99 million10.67 millionOptionableNATRNature's Sunshine Products85017.64 million16.65 millionOptionableNUTRNusatripN/A18.82 millionN/ANot OptionableVERUVeru23014.66 million12.43 millionOptionableNUTR, NATR, MED, and VERU HeadlinesRecent News About These CompaniesStealth resubmits rare disease drug to FDAAugust 18, 2025 | yahoo.comVeru Announces Novel Modified-Release Oral Formulation for EnobosarmAugust 15, 2025 | zacks.comVeru (NASDAQ:VERU) Price Target Lowered to $20.00 at Raymond James FinancialAugust 15, 2025 | marketbeat.comVeru Inc (VERU) Q3 2025 Earnings Report Preview: What To ExpectAugust 13, 2025 | finance.yahoo.comVeru Inc. Reports Positive Results and ProgressAugust 13, 2025 | msn.comVeru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program ProgressAugust 12, 2025 | finanznachrichten.deVeru Implements 1-for-10 Reverse Stock SplitAugust 12, 2025 | msn.comVeru Inc. (VERU) Stock Price Today - WSJAugust 12, 2025 | wsj.comVeru reports Q3 EPS (50c) vs. (75c) last yearAugust 12, 2025 | msn.comVeru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatmentAugust 12, 2025 | msn.comVeru Inc. (VERU) Q3 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comVeru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program ProgressAugust 12, 2025 | globenewswire.comVeru selects oral enobosarm formulation for developmentAugust 11, 2025 | thepharmaletter.comTA Look Ahead: Veru's Earnings ForecastAugust 11, 2025 | benzinga.comVeru Inc. Announces Novel Modified Release Oral Formulation of Enobosarm for Chronic Weight Loss ManagementAugust 11, 2025 | quiverquant.comQVeru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical StudyAugust 11, 2025 | globenewswire.comVeru trading halted, news pendingAugust 9, 2025 | msn.comVeru Announces Reverse Stock SplitAugust 6, 2025 | globenewswire.comVeru to Report Fiscal 2025 Third Quarter Financial Results on August 12thAugust 5, 2025 | finance.yahoo.comVeru Stock Short Interest Report | NASDAQ:VERU | BenzingaJuly 31, 2025 | benzinga.comVeru to Participate in the 2025 BTIG Virtual Biotech ConferenceJuly 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTake Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025Broadcom Named in Apple’s $100B U.S. Investment PlanBy Leo Miller | August 22, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s EndBy Thomas Hughes | August 19, 2025V2X Stock: Defense Underdog Riding a $4.3B Air Force ContractBy Nathan Reiff | August 24, 2025NUTR, NATR, MED, and VERU Company DescriptionsMEDIFAST NYSE:MED$14.21 +0.24 (+1.72%) Closing price 03:59 PM EasternExtended Trading$14.25 +0.04 (+0.27%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Nature's Sunshine Products NASDAQ:NATR$17.01 +0.05 (+0.29%) Closing price 04:00 PM EasternExtended Trading$17.02 +0.01 (+0.06%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Nusatrip NASDAQ:NUTRNutraceutical International Corporation is an integrated manufacturer, marketer, distributor and retailer of nutritional supplements and other natural products. The Company's products include vitamins and minerals; herbs; specialty formulas; personal care products; liquid nutritional products; homeopathics; functional foods, and other products. It offers its products to and through domestic health and natural food stores. It acts as a distributor to the Healthy Foods Channel and to certain international markets for certain third-party brands. It manufactures and sells nutritional supplements and other natural products under numerous brands, including Solaray, KAL, Dynamic Health, Nature's Life, LifeTime, Natural Balance, NaturalCare, Health from the Sun, Pioneer, Nutra BioGenesis, Life-flo, Organix South, Heritage Store and Monarch Nutraceuticals. It owns various natural food markets, such as The Real Food Company, Thom's Natural Foods, Cornucopia Community Market and Granola's.Veru NASDAQ:VERU$3.54 +0.09 (+2.61%) Closing price 04:00 PM EasternExtended Trading$3.54 +0.00 (+0.14%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
